BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang KW, Hsu FF, Qiu JT, Chern GJ, Lee YA, Chang CC, Huang YT, Sung YC, Chiang CC, Huang RL, Lin CC, Dinh TK, Huang HC, Shih YC, Alson D, Lin CY, Lin YC, Chang PC, Lin SY, Chen Y. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Sci Adv 2020;6:eaax5032. [PMID: 31998834 DOI: 10.1126/sciadv.aax5032] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Mainini F, Eccles MR. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy. Molecules 2020;25:E2692. [PMID: 32532030 DOI: 10.3390/molecules25112692] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
2 Giustarini G, Pavesi A, Adriani G. Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment. Front Bioeng Biotechnol 2021;9:689245. [PMID: 34150739 DOI: 10.3389/fbioe.2021.689245] [Reference Citation Analysis]
3 Isser A, Livingston NK, Schneck JP. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials 2021;268:120584. [PMID: 33338931 DOI: 10.1016/j.biomaterials.2020.120584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li Y, Hu P, Wang X, Hou X, Liu F, Jiang X. Integrin αvβ3-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma. Regen Biomater 2021;8:rbab046. [PMID: 34457350 DOI: 10.1093/rb/rbab046] [Reference Citation Analysis]
5 Pi YN, Xia BR, Jin MZ, Jin WL, Lou G. Exosomes: Powerful weapon for cancer nano-immunoengineering. Biochem Pharmacol 2021;186:114487. [PMID: 33647264 DOI: 10.1016/j.bcp.2021.114487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ljubimov VA, Ramesh A, Davani S, Danielpour M, Breunig JJ, Black KL. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Adv Drug Deliv Rev 2021;:114033. [PMID: 34808227 DOI: 10.1016/j.addr.2021.114033] [Reference Citation Analysis]
7 Bader CS, Jin L, Levy RB. STING and transplantation: can targeting this pathway improve outcomes? Blood 2021;137:1871-8. [PMID: 33619537 DOI: 10.1182/blood.2020008911] [Reference Citation Analysis]
8 Wu J, Chen J, Feng Y, Zhang S, Lin L, Guo Z, Sun P, Xu C, Tian H, Chen X. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles. Sci Adv 2020;6:eabc7828. [PMID: 32998884 DOI: 10.1126/sciadv.abc7828] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
9 Alexander CA, Yang YY. Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. Nanomedicine 2021;:102492. [PMID: 34775062 DOI: 10.1016/j.nano.2021.102492] [Reference Citation Analysis]
10 Boix-Montesinos P, Soriano-Teruel PM, Armiñán A, Orzáez M, Vicent MJ. The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev 2021;173:306-30. [PMID: 33798642 DOI: 10.1016/j.addr.2021.03.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
11 Elfiky AM, Mohamed RH, Abd El-Hakam FE, Yassin MA, ElHefnawi M. Targeted delivery of miR-218 via decorated hyperbranched polyamidoamine for liver cancer regression. Int J Pharm 2021;610:121256. [PMID: 34732362 DOI: 10.1016/j.ijpharm.2021.121256] [Reference Citation Analysis]
12 Hu D, Zhang W, Tang J, Zhou Z, Liu X, Shen Y. Improving safety of cancer immunotherapy via delivery technology. Biomaterials 2021;265:120407. [PMID: 32992118 DOI: 10.1016/j.biomaterials.2020.120407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Brücher D, Kirchhammer N, Smith SN, Schumacher J, Schumacher N, Kolibius J, Freitag PC, Schmid M, Weiss F, Keller C, Grove M, Greber UF, Zippelius A, Plückthun A. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. Mol Ther Methods Clin Dev 2021;20:572-86. [PMID: 33665227 DOI: 10.1016/j.omtm.2021.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Walters AA, Dhadwar B, Al-Jamal KT. Modulating expression of inhibitory and stimulatory immune 'checkpoints' using nanoparticulate-assisted nucleic acid delivery. EBioMedicine 2021;73:103624. [PMID: 34688033 DOI: 10.1016/j.ebiom.2021.103624] [Reference Citation Analysis]
15 Iorio M, Umesh Ganesh N, De Luise M, Porcelli AM, Gasparre G, Kurelac I. The Neglected Liaison: Targeting Cancer Cell Metabolic Reprogramming Modifies the Composition of Non-Malignant Populations of the Tumor Microenvironment. Cancers (Basel) 2021;13:5447. [PMID: 34771610 DOI: 10.3390/cancers13215447] [Reference Citation Analysis]
16 Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep 2021;3:100324. [PMID: 34381984 DOI: 10.1016/j.jhepr.2021.100324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Chizenga EP, Abrahamse H. Biological Therapy with Complementary and Alternative Medicine in Innocuous Integrative Oncology: A Case of Cervical Cancer. Pharmaceutics 2021;13:626. [PMID: 33924844 DOI: 10.3390/pharmaceutics13050626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang L, Yan Y. A Review of pH-Responsive Organic-Inorganic Hybrid Nanoparticles for RNAi-Based Therapeutics. Macromol Biosci 2021;:e2100183. [PMID: 34160896 DOI: 10.1002/mabi.202100183] [Reference Citation Analysis]
19 Est-witte SE, Livingston NK, Omotoso MO, Green JJ, Schneck JP. Nanoparticles for generating antigen-specific T cells for immunotherapy. Seminars in Immunology 2021. [DOI: 10.1016/j.smim.2021.101541] [Reference Citation Analysis]
20 Liu JY, Liu XY, Liu R, Tang F, Yang JB, Tang Q, Lu ZL, Qiao HJ, He L. Integration of [12]aneN3 and Acenaphtho[1,2-b]quinoxaline as non-viral gene vectors with two-photon property for enhanced DNA/siRNA delivery and bioimaging. Bioorg Chem 2021;113:104983. [PMID: 34029935 DOI: 10.1016/j.bioorg.2021.104983] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Baeza A. Tumor Targeted Nanocarriers for Immunotherapy. Molecules 2020;25:E1508. [PMID: 32225049 DOI: 10.3390/molecules25071508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
22 Bhattacharya D, Sakhare K, Narayan KP, Banerjee R. The prospects of nanotherapeutic approaches for targeting tumor-associated macrophages in oral cancer. Nanomedicine 2021;34:102371. [PMID: 33662592 DOI: 10.1016/j.nano.2021.102371] [Reference Citation Analysis]
23 Shams F, Golchin A, Azari A, Mohammadi Amirabad L, Zarein F, Khosravi A, Ardeshirylajimi A. Nanotechnology-based products for cancer immunotherapy. Mol Biol Rep 2021. [PMID: 34716502 DOI: 10.1007/s11033-021-06876-y] [Reference Citation Analysis]
24 Moin A, Wani SUD, Osmani RA, Abu Lila AS, Khafagy ES, Arab HH, Gangadharappa HV, Allam AN. Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer. Drug Deliv 2021;28:1626-36. [PMID: 34328806 DOI: 10.1080/10717544.2021.1958106] [Reference Citation Analysis]
25 Gupta B, Kim JO. Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices. J Pharm Investig 2021;51:399-412. [DOI: 10.1007/s40005-021-00527-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chen C, Yang RX, Xu HG. STING and liver disease. J Gastroenterol 2021;56:704-12. [PMID: 34159442 DOI: 10.1007/s00535-021-01803-1] [Reference Citation Analysis]
27 Zhao L, Luo Y, Huang Q, Cao Z, Yang X. Photo‐Enhanced CRISPR/Cas9 System Enables Robust PD‐L1 Gene Disruption in Cancer Cells and Cancer Stem‐Like Cells for Efficient Cancer Immunotherapy. Small 2020;16:2004879. [DOI: 10.1002/smll.202004879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sun B, Hyun H, Li LT, Wang AZ. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. Acta Pharmacol Sin 2020;41:970-85. [PMID: 32424240 DOI: 10.1038/s41401-020-0424-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
29 Chattopadhyay S, Hu CJ. Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination. Nanomedicine (Lond) 2020;15:2883-94. [PMID: 33252301 DOI: 10.2217/nnm-2020-0269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Nie W, Yu T, Liu X, Wang B, Li T, Wu Y, Zhou X, Ma L, Lin Y, Qian Z, Gao X. Non-viral vector mediated CKb11 with folic acid modification regulates macrophage polarization and DC maturation to elicit immune response against cancer. Bioact Mater 2021;6:3678-91. [PMID: 33898872 DOI: 10.1016/j.bioactmat.2021.03.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gao Y, Men K, Pan C, Li J, Wu J, Chen X, Lei S, Gao X, Duan X. Functionalized DMP-039 Hybrid Nanoparticle as a Novel mRNA Vector for Efficient Cancer Suicide Gene Therapy. Int J Nanomedicine 2021;16:5211-32. [PMID: 34366664 DOI: 10.2147/IJN.S319092] [Reference Citation Analysis]
32 Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol 2021; 13(10): 1213-1228 [PMID: 34721763 DOI: 10.4251/wjgo.v13.i10.1213] [Reference Citation Analysis]
33 Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev 2020;154-155:64-78. [PMID: 32768564 DOI: 10.1016/j.addr.2020.07.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
34 Wu S, Xia Y, Hu Y, Ma G. Bio-mimic particles for the enhanced vaccinations: Lessons learnt from the natural traits and pathogenic invasion. Adv Drug Deliv Rev 2021;:113871. [PMID: 34311014 DOI: 10.1016/j.addr.2021.113871] [Reference Citation Analysis]
35 Rawding PA, Bu J, Wang J, Kim DW, Drelich AJ, Kim Y, Hong S. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1752. [PMID: 34414690 DOI: 10.1002/wnan.1752] [Reference Citation Analysis]
36 Sun Q, Yang Z, Lin M, Peng Y, Wang R, Du Y, Zhou Y, Li J, Qi X. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers. Biomaterials 2021;269:120648. [PMID: 33445099 DOI: 10.1016/j.biomaterials.2020.120648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Liu Y, Wang Y, Song S, Zhang H. Tumor Diagnosis and Therapy Mediated by Metal Phosphorus-Based Nanomaterials. Adv Mater 2021;:e2103936. [PMID: 34596931 DOI: 10.1002/adma.202103936] [Reference Citation Analysis]
38 Ziemba B, Borowiec M, Franiak-Pietryga I. There and back again: a dendrimer's tale. Drug Chem Toxicol 2021;:1-16. [PMID: 33910437 DOI: 10.1080/01480545.2021.1915327] [Reference Citation Analysis]
39 Lakshmanan VK, Jindal S, Packirisamy G, Ojha S, Lian S, Kaushik A, Alzarooni AIMA, Metwally YAF, Thyagarajan SP, Do Jung Y, Chouaib S. Nanomedicine-based cancer immunotherapy: recent trends and future perspectives. Cancer Gene Ther 2021. [PMID: 33558704 DOI: 10.1038/s41417-021-00299-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
40 Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021;20:101-24. [PMID: 33277608 DOI: 10.1038/s41573-020-0090-8] [Cited by in Crossref: 182] [Cited by in F6Publishing: 173] [Article Influence: 91.0] [Reference Citation Analysis]
41 Van Herck S, Feng B, Tang L. Delivery of STING agonists for adjuvanting subunit vaccines. Adv Drug Deliv Rev 2021;179:114020. [PMID: 34756942 DOI: 10.1016/j.addr.2021.114020] [Reference Citation Analysis]
42 Mohammadinejad R, Dehshahri A, Sagar Madamsetty V, Zahmatkeshan M, Tavakol S, Makvandi P, Khorsandi D, Pardakhty A, Ashrafizadeh M, Ghasemipour Afshar E, Zarrabi A. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release 2020;325:249-75. [PMID: 32634464 DOI: 10.1016/j.jconrel.2020.06.038] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
43 Saeed M, Chen F, Ye J, Shi Y, Lammers T, De Geest BG, Xu ZP, Yu H. From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. Adv Mater 2021;33:e2008094. [PMID: 34048101 DOI: 10.1002/adma.202008094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Thangam R, Patel KD, Kang H, Paulmurugan R. Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives. Vaccines (Basel) 2021;9:935. [PMID: 34452059 DOI: 10.3390/vaccines9080935] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Trosheva KS, Sorokina SA, Efimova АА, Semenyuk PI, Berkovich AK, Yaroslavov AA, Shifrina ZB. Interaction of multicomponent anionic liposomes with cationic pyridylphenylene dendrimer: Does the complex behavior depend on the liposome composition? Biochim Biophys Acta Biomembr 2021;1863:183761. [PMID: 34480877 DOI: 10.1016/j.bbamem.2021.183761] [Reference Citation Analysis]